Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens

Nuvation Bio Inc shares tumbled almost 18% on Monday following news of a licensing deal with Japan’s Eisai and initial sales data for its lung-cancer treatment. The stock slipped 17.7% to $6.62, after fluctuating between $8.34 and $6.32 on roughly 11.4 million shares traded.

Japan Stock Market Today: Nikkei 225 Ends Flat as SoftBank Crashes on AI Jitters – November 25, 2025

Japan Stock Market Today: Nikkei 225 Ends Flat as SoftBank Crashes on AI Jitters – November 25, 2025

TOKYO – Japan’s stock market eked out a marginal gain on Tuesday, November 25, as an early tech-led rally faded into a mixed close. The Nikkei 225 finished just 0.07% higher at 48,659.52, while the broader Topix slipped 0.21% to 3,290.89.FRED+3Xinhua News+3The Economic Times+3
Science Shockers: AI-Created Viruses, “Water Worlds” Debunked & More (Sept 19–20, 2025)

Science Shockers: AI-Created Viruses, “Water Worlds” Debunked & More (Sept 19–20, 2025)

AI Designs New Viruses: In a stunning demonstration of AI’s creative power, scientists announced they have used artificial intelligence to design the first-ever viruses from scratch. The AI wrote complete viral genomes for bacteriophages which were then synthesized in the lab nature.com. Several of these AI-generated phages successfully infected and killed E. coli bacteria that natural phages couldn’t attack nature.com. “This is the first time AI systems are able to write coherent genome-scale sequences,” said Stanford computational biologist Brian Hie, calling it a step toward “AI-generated life” nature.com. While still in preprint and not yet peer-reviewed, the breakthrough suggests AI could become a powerful tool for engineering new biomedical therapies nature.com nature.com. Researchers hope AI-designed phages might one day help fight antibiotic-resistant superbugs nature.com nature.com – showcasing a real-world payoff for AI in medicine. The work also raises biosafety questions, as wholly novel organisms can now be created digitally, underscoring the need for oversight as “the next step is AI-generated life,” in Hie’s words nature.com.
Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

Alzheimer’s At-Home Shot Approved, Bird Flu Scare, and CDC Shake-Up – Global Biotech & Health Roundup (Aug 29–30, 2025)

Leading our roundup are several significant scientific and medical breakthroughs. Researchers in New York unveiled a potential “universal” antiviral strategy, reporting compounds that neutralized seven different viruses across multiple families in lab tests gavi.org. By targeting sugar molecules common to many enveloped viruses, the team identified four small molecules that blocked infections by pathogens ranging from coronaviruses to Nipah and Ebola gavi.org. “This is the kind of antiviral tool the world urgently needs. If a new virus emerges tomorrow, we currently have nothing to deploy. These compounds offer the potential to be that first line of defence,” said Dr. Adam Braunschweig of CUNY, who led the study gavi.org. The findings, published in Science Advances, mark an early proof-of-concept for broad-spectrum antivirals, though further work is needed to advance these candidates into animal and human trials. Experts note this approach could be game-changing in future pandemics, filling the gap while vaccines and virus-specific drugs are developed gavi.org.

US Stock Market Today Updates

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 Strong Buy

NVIDIA

94/100
#2 Strong Buy

Meta Platforms

89/100
#3 Buy

Alphabet

87/100
#4 Buy

Amazon

84/100
#5 Selective Buy

Microsoft

80/100
View full portfolio
Editorial model selection. Not personalised advice.
MARKET CALENDAR

Key Events Today

The catalysts most likely to move markets.

#1

Warsh at Jackson Hole

Policy tone can move rates, USD, equities, gold and crypto simultaneously.

#2

Michigan sentiment

A weak final reading or elevated inflation expectations could pressure risk assets.

#3

Chicago PMI

A surprise versus 58.0 may alter the near-term manufacturing-growth narrative.

View full calendar
Times and estimates may change. Verify before trading.